Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe

AP Kennedy, KC Mangum, J Linden and JN Wells

Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA.

Structure-based design of subtype-selective ligands for the A1 adenosine receptor will require a reliable model of the ligand-binding pocket. It should be possible to develop a reliable model based on the results of affinity labeling experiments that provide atomic coordinates for the ligand in relation to predicted receptor helices. A high affinity, A1-selective xanthine antagonist photoaffinity probe, 125l-3-(4-azidophenethyl)-1-propyl-B-cyclopentylxanthine, was used to covalently modify the A1 receptor. Chemical or enzymatic fragmentation experiments were performed to localize the region or regions of incorporation within the receptor. The fragmentation profiles for radiolabeled A1 receptor obtained with endoproteinase Glu-C, endoproteinase Lys-C, cyanogen bromide, and hydroxylamine were consistent with the interpretation that the covalent linkage was within the first four predicted transmembrane regions. This interpretation was confirmed by the demonstration that the radioactive endoproteinase Glu- C fragment derived from an A1 receptor that contains an amino-terminal FLAG epitope was recognized by an anti-FLAG monoclonal antibody. Sequential digestion with endoproteinase Glu-C/endoproteinase Lys-C limited the possible labeling to the first three predicted transmembrane spans, and endoproteinase Glu-C/trypsin digestion refined this prediction to include only transmembrane spans III and IV. Taken together, our findings suggest that the adenosine antagonist 125l-3-(4- azidophenethyl)-1-propyl-8-cyclopentyl-xanthine covalently modifies transmembrane III of the A1 receptor because this was the only receptor region common to all radiolabeled fragments.

Volume 50, Issue 4, pp. 789-798, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Clement, S. S. Martin, M.-E. Beaulieu, C. Chamberland, P. Lavigne, R. Leduc, G. Guillemette, and E. Escher Determining the Environment of the Ligand Binding Pocket of the Human Angiotensin II Type I (hAT1) Receptor Using the Methionine Proximity Assay J. Biol. Chem., July 22, 2005; 280(29): 27121 - 27129. [Abstract] [Full Text] [PDF]

				B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552. [Abstract] [Full Text] [PDF]

				S. A. Laporte, A. A. Boucard, G. Servant, G. Guillemette, R. Leduc, and E. Escher Determination of Peptide Contact Points in the Human Angiotensin II Type I Receptor (AT1) with Photosensitive Analogs of Angiotensin II Mol. Endocrinol., April 1, 1999; 13(4): 578 - 586. [Abstract] [Full Text]

				S. A. Rivkees, H. Barbhaiya, and A. P. IJzerman Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor J. Biol. Chem., February 5, 1999; 274(6): 3617 - 3621. [Abstract] [Full Text] [PDF]